Objectives: The aim of this study was to compare health-related quality of life (HRQoL) scores obtained from the instrument Short Form (SF)-36 through the so-called SF-6D utilities, and those obtained from 15D, in patients with ST-elevation myocardial infarction (STEMI), and to evaluate the consequences in estimation of quality adjusted life years (QALYs).
Design: This was a sub-study of the Norwegian District Treatment of STEMI, in which patients with STEMI treated with tenecteplase, were randomized to early angioplasty or standard management (n = 266). HRQoL data were collected at all visits (0, 1, 3, 7 and 12 months). All patients with complete data were included (n = 248).
Results: The score range was 0.33-1.0 for SF-6D and 0.49-1.0 for 15D. Mean utility scores from 15D were higher and had different distribution compared to scores from SF-6D. Mean QALY for the whole group was higher using 15D than SF-6D (0.89 vs. 0.77). The incremental number of QALYs with early angioplasty compared to standard treatment was 0.005 (95% CI: - 0.018 to 0.028) using SF-6D, and 0.004 (95% CI: - 0.010 to 0.018) using the 15D instrument.
Conclusions: Choice of instrument may influence HRQoL scores, but not necessarily the gain in QALYs.
Trial registration: ClinicalTrials.gov NCT00161005.
Keywords: SF-6D; Sintonen 15D; coronary heart disease; quality of life; quality-adjusted life years; randomized controlled trial.